HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.107.039487v1 48/8/1327    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garrison, J. C. Articles by Hoffman, T. J. Search for Related Content PubMed PubMed Citation Articles by Garrison, J. C. Articles by Hoffman, T. J.

In Vivo Evaluation and Small-Animal PET/CT of a Prostate Cancer Mouse Model Using ⁶⁴Cu Bombesin Analogs: Side-by-Side Comparison of the CB-TE2A and DOTA Chelation Systems

¹ Harry S. Truman Memorial VA Hospital, Columbia, Missouri; ² Department of Internal Medicine, University of Missouri–Columbia School of Medicine, Columbia, Missouri; ³ Department of Radiology, University of Missouri–Columbia School of Medicine, Columbia, Missouri; and ⁴ Department of Chemistry, University of Missouri–Columbia, Columbia, Missouri

Correspondence: For correspondence or reprints contact: Timothy J. Hoffman, PhD, Harry S. Truman Veterans' Hospital, 800 Hospital Dr. F-003, Columbia, MO 65201-5275. E-mail: HoffmanT{at}health.missouri.edu

The BB2 receptor subtype, of the bombesin family of receptors, has been shown to be highly overexpressed in a variety of human tumors, including prostate cancer. Bombesin (BBN), a 14-amino acid peptide, has been shown to target the BB2 receptor with high affinity. ⁶⁴Cu (half-life = 12.7 h, ß⁺: 18%, E_ß+max = 653 keV; ß^–: 37%, E_ß–max = 578 keV) is a radioisotope that has clinical potential for application in both diagnostic imaging and radionuclide therapy. Recently, new chelation systems such as 1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid (CB-TE2A) have been reported to significantly stabilize the ⁶⁴Cu radiometal in vivo. The increased stability of the ⁶⁴Cu-CB-TE2A chelate complex has been shown to significantly reduce nontarget retention compared with tetraazamacrocycles such as 1,4,7,10-tetraazacyclodoadecane-N,N',N'',N'''-tetraacetic acid (DOTA). The aim of this study was to determine whether the CB-TE2A chelation system could significantly improve the in vivo stability of ⁶⁴Cu bombesin analogs. The study directly compares ⁶⁴Cu bombesin analogs using the CB-TE2A and DOTA chelation systems in a prostate cancer xenograft SCID (severely compromised immunodeficient) mouse model. Methods: The CB-TE2A-8-AOC-BBN(7–14)NH₂ and DOTA-8-AOC-BBN(7–14)NH₂ conjugates were synthesized and radiolabeled with ⁶⁴Cu. The receptor-binding affinity and internalization profile of each metallated conjugate was evaluated using PC-3 cells. Pharmacokinetic and small-animal PET/CT studies were performed using female SCID mice bearing PC-3 xenografts. Results: In vivo BB2 receptor targeting was confirmed by tumor uptake values of 6.95 ± 2.27 and 4.95 ± 0.91 %ID/g (percentage injected dose per gram) at the 15-min time point for the ⁶⁴Cu-CB-TE2A and ⁶⁴Cu-DOTA radioconjugates, respectively. At the 24-h time point, liver uptake was substantially reduced for the ⁶⁴Cu-CB-TE2A radioconjugate (0.21 ± 0.06 %ID/g) compared with the ⁶⁴Cu-DOTA radioconjugate (7.80 ± 1.51 %ID/g). The ⁶⁴Cu-CB-TE2A-8-AOC-BBN(7–14)NH₂ radioconjugate demonstrated significant clearance, 98.60 ± 0.28 %ID, from the mouse at 24 h after injection. In contrast, only 67.84 ± 5.43 %ID of the ⁶⁴Cu activity was excreted using the ⁶⁴Cu-DOTA-8-AOC-BBN(7–14)NH₂ radioconjugate because of nontarget retention. Conclusion: The pharmacokinetic and small-animal PET/CT studies demonstrate significantly improved nontarget tissue clearance for the ⁶⁴Cu-CB-TE2A8-AOC-BBN(7–14)NH₂. This is attributed to the improved in vivo stability of the ⁶⁴Cu-CB-TE2A chelate complex as compared with the ⁶⁴Cu-DOTA chelate complex.

Key Words: BB2 receptor • bombesin • ⁶⁴Cu • preclinical • prostate cancer

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  

This article has been cited by other articles:

				Z. Liu, Z.-B. Li, Q. Cao, S. Liu, F. Wang, and X. Chen Small-Animal PET of Tumors with 64Cu-Labeled RGD-Bombesin Heterodimer J. Nucl. Med., July 1, 2009; 50(7): 1168 - 1177. [Abstract] [Full Text] [PDF]

				J. V. Leyton, T. Olafsen, E. J. Lepin, S. Hahm, K. B. Bauer, R. E. Reiter, and A. M. Wu Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen-Expressing Tumors Clin. Cancer Res., November 15, 2008; 14(22): 7488 - 7496. [Abstract] [Full Text] [PDF]

				R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF]